Literature DB >> 24395136

Striatal volume deficits in children with ADHD who present a poor response to methylphenidate.

A Moreno1, L Duñó, E Hoekzema, M Picado, L M Martín, J Fauquet, Y Vives-Gilabert, A Bulbena, O Vilarroya.   

Abstract

Methylphenidate (MPH) is the first choice of medical treatment for attention-deficit/hyperactivity disorder (ADHD). Its mechanism of action is to inhibit the reuptake of dopamine and noradrenaline mainly in the region of the striatum. It has been estimated that 10-30 % of patients with ADHD do not respond adequately to MPH. The aim of this study was to evaluate whether striatal differences exist between good and poor responders to MPH. The sample included 27 treatment-naïve children with ADHD between the ages of 6 and 14. MPH administration started 1 day after the MRI acquisition. After a month, psychiatrists established the good or poor response to treatment according to clinical criteria. MRI images were analyzed using a technique based on regions of interest applied specifically to the caudate and accumbens nuclei. Sixteen patients showed good response to MPH and 11 a poor one. Regions of interest analysis showed that good responders had a higher concentration of gray matter in the head of both caudate nuclei and the right nucleus accumbens. Furthermore, a significant correlation was found between caudate and accumbens nuclei volume and the Conners' Parent Rating Scale and Continuous Performance Test improvement. These results support the hypothesis of the involvement of the caudate and accumbens nuclei in MPH response and in ADHD pathophysiology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24395136     DOI: 10.1007/s00787-013-0510-y

Source DB:  PubMed          Journal:  Eur Child Adolesc Psychiatry        ISSN: 1018-8827            Impact factor:   4.785


  46 in total

1.  Methylphenidate-elicited dopamine increases in ventral striatum are associated with long-term symptom improvement in adults with attention deficit hyperactivity disorder.

Authors:  Nora D Volkow; Gene-Jack Wang; Dardo Tomasi; Scott H Kollins; Tim L Wigal; Jeffrey H Newcorn; Frank W Telang; Joanna S Fowler; Jean Logan; Christopher T Wong; James M Swanson
Journal:  J Neurosci       Date:  2012-01-18       Impact factor: 6.167

2.  Revision and restandardization of the Conners Teacher Rating Scale (CTRS-R): factor structure, reliability, and criterion validity.

Authors:  C K Conners; G Sitarenios; J D Parker; J N Epstein
Journal:  J Abnorm Child Psychol       Date:  1998-08

3.  Gray matter volume abnormalities in ADHD: voxel-based meta-analysis exploring the effects of age and stimulant medication.

Authors:  Tomohiro Nakao; Joaquim Radua; Katya Rubia; David Mataix-Cols
Journal:  Am J Psychiatry       Date:  2011-08-24       Impact factor: 18.112

4.  Volumetric MRI analysis comparing subjects having attention-deficit hyperactivity disorder with normal controls.

Authors:  P A Filipek; M Semrud-Clikeman; R J Steingard; P F Renshaw; D N Kennedy; J Biederman
Journal:  Neurology       Date:  1997-03       Impact factor: 9.910

Review 5.  Effects of stimulants on the continuous performance test (CPT): implications for CPT use and interpretation.

Authors:  C A Riccio; J J Waldrop; C R Reynolds; P Lowe
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2001       Impact factor: 2.198

6.  Executive impairment determines ADHD medication response: implications for academic achievement.

Authors:  James B Hale; Linda A Reddy; Margaret Semrud-Clikeman; Lisa A Hain; James Whitaker; Jessica Morley; Kyle Lawrence; Alex Smith; Nicole Jones
Journal:  J Learn Disabil       Date:  2011 Mar-Apr

7.  Ventro-striatal reductions underpin symptoms of hyperactivity and impulsivity in attention-deficit/hyperactivity disorder.

Authors:  Susanna Carmona; Erika Proal; Elseline A Hoekzema; Juan-Domingo Gispert; Marisol Picado; Irene Moreno; Juan Carlos Soliva; Anna Bielsa; Mariana Rovira; Joseph Hilferty; Antonio Bulbena; Miquel Casas; Adolf Tobeña; Oscar Vilarroya
Journal:  Biol Psychiatry       Date:  2009-07-03       Impact factor: 13.382

8.  Cerebral morphology and dopamine D2/D3 receptor distribution in humans: a combined [18F]fallypride and voxel-based morphometry study.

Authors:  Neil D Woodward; David H Zald; Zhaohua Ding; Patrizia Riccardi; M Sib Ansari; Ronald M Baldwin; Ronald L Cowan; Rui Li; Robert M Kessler
Journal:  Neuroimage       Date:  2009-02-05       Impact factor: 6.556

9.  National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment.

Authors: 
Journal:  Pediatrics       Date:  2004-04       Impact factor: 7.124

10.  Which treatment for whom for ADHD? Moderators of treatment response in the MTA.

Authors:  Elizabeth B Owens; Stephen P Hinshaw; Helen C Kraemer; L Eugene Arnold; Howard B Abikoff; Dennis P Cantwell; C Keith Conners; Glen Elliott; Laurence L Greenhill; Lily Hechtman; Betsy Hoza; Peter S Jensen; John S March; Jeffrey H Newcorn; William E Pelham; Joanne B Severe; James M Swanson; Benedetto Vitiello; Karen C Wells; Timothy Wigal
Journal:  J Consult Clin Psychol       Date:  2003-06
View more
  3 in total

1.  Attenuated Tonic and Enhanced Phasic Release of Dopamine in Attention Deficit Hyperactivity Disorder.

Authors:  Rajendra D Badgaiyan; Sampada Sinha; Munawwar Sajjad; David S Wack
Journal:  PLoS One       Date:  2015-09-30       Impact factor: 3.240

2.  Subcortical volumetric alterations as potential predictors of methylphenidate treatment response in youth with attention-deficit/hyperactivity disorder.

Authors:  Ji-Sahn Kim; Kyung Hwa Lee; Chan-Sop Hwang; Jae-Won Kim
Journal:  J Psychiatry Neurosci       Date:  2022-01-13       Impact factor: 6.186

Review 3.  Treatment biomarkers for ADHD: Taking stock and moving forward.

Authors:  Giorgia Michelini; Luke J Norman; Philip Shaw; Sandra K Loo
Journal:  Transl Psychiatry       Date:  2022-10-12       Impact factor: 7.989

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.